SynthesisFrontiers in oncology2026
A systematic review of immune checkpoint inhibitors in endometrial cancer.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometrial cancer represents one of the most prevalent gynecological malignancies. This study aims to systematically analyze the knowledge frameworks, key contributors, research hotspots, emerging trending topics, and future directions in the field of immune checkpoint inhibitors for endometrial cancer by applying bibliometric methodologies. Methods: A thorough and methodical search of the Web of Science Core Collection (WoSCC) database and the PubMed database was performed to identify publications related to immune checkpoint inhibitors in endometrial cancer from January 1, 2015, to December 31, 2024. Furthermore, bibliometric analysis and knowledge map visualization were conducted utilizing VOSviewer, Biblioshiny, and CiteSpace. Results: For the WoSCC database, this research involved an analysis of 829 publications disseminated across 296 journals, authored by 5,145 researchers affiliated with 1,535 institutions from 63 different countries. For the PubMed database, this research involved an analysis of 279 publications disseminated across 120 journals, authored by 1,611 researchers affiliated with 974 institutions from 46 different countries. The leading three contributors to publication volume were United States, China, and Italy. Importantly, the highest level of international collaboration has been recorded between United States and England. Gynecologic Oncology, Cancers, Frontiers in Immunology, Frontiers in Oncology, and the Journal of Clinical Oncology are acknowledged as the five most influential journals regarding immune checkpoint inhibitors for endometrial cancer. Makker Vicky emerged as the most influential author, while Memorial Sloan Kettering Cancer Center was identified as the most influential institution. Current research hotspots regarding immune checkpoint inhibitors in the treatment of endometrial cancer include microsatellite instability, mismatch repair deficiency, PD-1, PD-L1, chemotherapy, pembrolizumab, lenvatinib, and dostarlimab. Additionally, emerging trending topics in this field encompass pembrolizumab, lenvatinib, dostarlimab, immune checkpoint inhibitors, and mismatch repair deficiency. Conclusion: An in-depth exploration of the molecular mechanisms of immune checkpoint inhibitors for endometrial cancer is crucial for overcoming the current clinical challenges associated with immunotherapy. This study systematically analyzes the current state of research in this field, focusing on research hotspots, emerging trends, and future development directions. Additionally, it comprehensively evaluates the most influential literature, core journals, authoritative scholars, leading research institutions, and major contributing countries in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.